Literature DB >> 16885368

The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.

Farid Gizatullin1, Yao Yao, Victor Kung, Matthew W Harding, Massimo Loda, Geoffrey I Shapiro.   

Abstract

VX-680 is a potent inhibitor of Aurora kinases that induces the accumulation of cells with > or =4N DNA content, followed by cell death. Here, we define the role of p53 and p21(Waf1/Cip1) in cell cycle perturbations following exposure to VX-680. Endoreduplication and apoptosis in response to VX-680 are limited in A549 and MCF-7 cells expressing wild-type p53, and markedly enhanced in cells lacking p53, including those engineered to express the HPV16-E6 oncoprotein or short interfering RNA pools targeting p53. In contrast, endoreduplication and apoptosis occur in the p53 wild-type cell lines, RKO and U2OS. The difference in response to VX-680 among these cell lines correlates with the timing of induction of p21(Waf1/Cip1) and its ability to inhibit cyclin E-cdk2 activity. In A549 cells, VX-680 induces the expression of p53 and p21(Waf1/Cip1) within 24 hours, with consequent inhibition of cyclin E-cdk2, and reduction of retinoblastoma protein phosphorylation, limiting endoreduplication. In RKO and U2OS cells, the induction of p21(Waf1/Cip1) is delayed and associated with higher residual cyclin E-cdk2 kinase activity and retinoblastoma protein phosphorylation, followed by progressive endoreduplication and apoptosis. Abrogation of p21(Waf1/Cip1) expression by short interfering RNA targeting in A549 cells results in a substantial increase in the degree of endoreduplication, whereas inducible expression of p21(Waf1/Cip1) in p53-negative NCI-H1299 cells inhibits VX-680-induced endoreduplication and cell death. These data suggest that the integrity of the p53-p21(Waf1/Cip1)-dependent postmitotic checkpoint governs the response to Aurora kinase inhibition. Although cells with intact checkpoint function arrest with 4N DNA content, those with compromised checkpoint function are more likely to undergo endoreduplication followed by eventual apoptosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885368     DOI: 10.1158/0008-5472.CAN-05-3353

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  68 in total

1.  The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.

Authors:  Jayasree S Nair; Alan L Ho; Gary K Schwartz
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

Review 2.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

3.  Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.

Authors:  Jayasree S Nair; Alan L Ho; Archie N Tse; Jesse Coward; Haider Cheema; Grazia Ambrosini; Nicholas Keen; Gary K Schwartz
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

4.  Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK.

Authors:  Rong Huang; Hyunju Oh; Allison Arrendale; Victoria A Martin; Jacob Galan; Eric J Workman; Jane R Stout; Claire E Walczak; W Andy Tao; Richard F Borch; Robert L Geahlen
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

Review 5.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

Review 6.  Target validation and biomarker identification in oncology : the example of aurora kinases.

Authors:  Riccardo Colombo; Jürgen Moll
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Depletion of Aurora A leads to upregulation of FoxO1 to induce cell cycle arrest in hepatocellular carcinoma cells.

Authors:  Sun-Young Lee; Gong Rak Lee; Dong-Hyuk Woo; Neung Hwa Park; Hee Jeong Cha; Yong-Hwan Moon; In-Seob Han
Journal:  Cell Cycle       Date:  2013-01-01       Impact factor: 4.534

8.  Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Authors:  Matthew P Martin; Yunting Luo; Roberta Pireddu; Hua Yang; Harsukh Gevariya; Harshani R Lawrence; Sevil Ozcan; Jin-Yi Zhu; Robert Kendig; Mercedes Rodriguez; Roy Elias; Jin Q Cheng; Saïd M Sebti; Ernst Schonbrunn; Nicholas J Lawrence
Journal:  J Med Chem       Date:  2012-08-30       Impact factor: 7.446

9.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

Review 10.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.